Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Receivables - Other (2018 - 2025)

Historic Receivables - Other for China SXT Pharmaceuticals (SXTC) over the last 8 years, with Q3 2025 value amounting to $19658.0.

  • China SXT Pharmaceuticals' Receivables - Other rose 11636.5% to $19658.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $19658.0, marking a year-over-year increase of 11636.5%. This contributed to the annual value of $417563.0 for FY2025, which is 39927.42% up from last year.
  • Latest data reveals that China SXT Pharmaceuticals reported Receivables - Other of $19658.0 as of Q3 2025, which was up 11636.5% from $417563.0 recorded in Q1 2025.
  • China SXT Pharmaceuticals' 5-year Receivables - Other high stood at $3.0 million for Q3 2021, and its period low was -$120122.0 during Q3 2024.
  • Its 5-year average for Receivables - Other is $790443.8, with a median of $230642.0 in 2023.
  • Per our database at Business Quant, China SXT Pharmaceuticals' Receivables - Other skyrocketed by 54285.4% in 2021 and then tumbled by 6373.86% in 2024.
  • China SXT Pharmaceuticals' Receivables - Other (Quarter) stood at $3.0 million in 2021, then decreased by 7.72% to $2.7 million in 2022, then tumbled by 91.61% to $230642.0 in 2023, then crashed by 152.08% to -$120122.0 in 2024, then soared by 116.37% to $19658.0 in 2025.
  • Its Receivables - Other stands at $19658.0 for Q3 2025, versus $417563.0 for Q1 2025 and -$120122.0 for Q3 2024.